[Guidelines for the management of Crohn's disease]

Byong Duk Ye1, Suk-Kyun Yang, Sung Jae Shin

  • 1Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.

Insights

This study introduces the first Korean guidelines for managing Crohn's disease (CD), a chronic inflammatory bowel disease (IBD). These guidelines aim to standardize treatment approaches for various CD complications and patient scenarios in Korea.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Clinical Practice Guidelines

Background:

  • Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with increasing incidence in Korea.
  • Current CD management often relies on physician experience, leading to variability in care.
  • Serious complications of CD include strictures, perforations, and fistulas.

Purpose of the Study:

  • To develop the first Korean guidelines for the management of Crohn's disease (CD).
  • To provide standardized approaches for diverse CD clinical situations and complications.
  • To minimize variations in CD management decisions among physicians.

Main Methods:

  • Adaptation methods were used to develop the guidelines.
  • Guidelines cover treatment of inflammatory, stricturing, and penetrating CD.
  • Recommendations include surgical indications, post-operative recurrence prevention, and management during pregnancy/lactation.

Main Results:

  • The guidelines provide a comprehensive framework for CD management in Korea.
  • They address various disease manifestations, including inflammation, strictures, and penetrating disease.
  • Specific recommendations are provided for surgical interventions and special patient populations.

Conclusions:

  • These represent the first Korean guidelines for Crohn's disease management.
  • The guidelines aim to standardize care and improve outcomes for IBD patients in Korea.
  • Future updates incorporating new scientific evidence are necessary.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...